Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 9, 1997, Pages 361-365

  Brewster, M E ^a,b   Pop, E ^a   Foltz, R L ^c   Reuschel, S ^c   Griffith, W ^d   Amselem, S ^b   Biegon, A ^b  

^a Pharmos Corporation   (United States)

^b PHARMOS LTD   (Israel)

^c Northwest Toxicology Inc   (United States)

^d Pharmakopius International   (United Kingdom)

Author keywords

Cannabinoids; Dexanabinol (HU 211); Human; Neuroprotectant; Pharmacokinetics

Indexed keywords

CANNABINOID; DEXANABINOL; DRUG VEHICLE; NEUROPROTECTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NEUROPROTECTIVE AGENTS; TETRAHYDROCANNABINOL;

EID: 0030827712     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21-43
2. Belayev L, Busto R, Zhao W, Ginsberg M 1995 HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 26: 2313-2319
3. Biegon A, Bar-Joseph A 1995 Development of HU-211 as a neuroprotectant for ischemic brain damage. Neurol Res 17: 275-280
4. Choi D 1988 Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634
5. Dietzel K, Estes K, Brewster M, Bodor N, Derendorf H 1990 The use of hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. Int J Pharm 59; 225-230
6. Eshhar N, Striem S, Biegon A 1993 HU-211, a nonpsychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuro Repts 6; 237-240
7. Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A 1995 Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor anatgonist. Eur J Pharmacol 283:19-29
8. Feigenbaum J, Bergmann F, Richmond S, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M 1989 Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci USA 86: 9584-9587
9. Lorenz W, Reimann H, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A 1977 Histamine release in dogs by Cremophor EL and its derivatives, oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63-67
10. Mechoulam R, Feigenbaum J, Lander N, Segal M, Järbe T, Hiltunen A, Consroe P 1988 Enatiomeric cannabinoids: stereospecificity of psychotropic action. Experientia 44: 762-764
11. ++ influx through the N-methyl-D-aspartate receptor ion channel by the nonpsychoactive cannabinoid HU-211. Brain Res 622: 79-85
12. National Center for Health Statistics 1993 Monthly Vital Statistics Report, Public Health Service 42
13. 9-tetrahydrocannabinol, naltrexone and their active metabolites in plasma. Ther Drug Mon 15: 557-562
14. Pop E, Browne C E, Nodler V, Biegen A, Brewster M 1996 Neuroprotective (+) 3S, 4S cannabinoids with modified 5′-side chain. Bioorg Med Chem Lett 6: 1553-1558
15. Shohami E, Novikov M, Bass R 1995 Long-term effect of HU-211, a novel noncompetitive NMDA antagonist, on motor and memory function after closed head injury in the rat. Brain Res 674: 55-62
16. Sosin D, Sacks J, Smith S 1989 Head injury associated deaths in the United States from 1979-1986. JAMA 262: 2251-2256
17. Wade A, Weller P 1994 Handbook of pharmaceutical excipients. American Pharmaceutical Association, Washington, pp 371-374